Bharat Biotech says its trial of Covaxin booster jabs has demonstrated “long-term safety with no serious adverse events” “90% of recipients had a detectable neutralizing antibody response against the wild-type strain (6 months after the second dose),” the Covaxin maker says
Bharat Biotech says its trial of Covaxin booster jabs has demonstrated “long-term safety with no serious adverse events” “90%
